Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

Trends in Pharmacological Sciences

Volumn 29, Issue 8, 2008, Pages 383-390

  Melero, Ignacio ^a,b   Murillo, Oihana ^a   Dubrot, Juan ^a   Hervás Stubbs, Sandra ^a   Perez Gracia, José L ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL TYPE; CELLULAR IMMUNITY; CROSS LINKING; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; INTERNALIZATION; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 47849106040     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.05.005     Document Type: Article

References (59)

1. Vinay D.S., et al. Dual immunoregulatory pathways of 4-1BB signaling. J. Mol. Med. 84 (2006) 726-736
2. Kwon B.S., and Weissman S.M. cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 1963-1967
3. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23 (2005) 23-68
4. Drenkard D., et al. CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J. 21 (2007) 456-463
5. Melero I., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3 (1997) 682-685
6. Sun Y., et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. 8 (2002) 1405-1413
7. Seo S.K., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10 (2004) 1088-1094
8. Myers L.M., and Vella A.T. Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol. 26 (2005) 440-446
9. + T cells and inhibit tumor growth in mice. J. Clin. Invest. 118 (2008) 376-386
10. Melero I., et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7 (2007) 95-106
11. Lynch D.H. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol. Rev. 222 (2008) 277-286
12. Uno T., et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12 (2006) 693-698
13. McMillin D.W., et al. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. Hum. Gene Ther. 17 (2006) 798-806
14. Shi W., and Siemann D.W. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res. 26 (2006) 3445-3453
15. Wilcox R.A., et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109 (2002) 651-659
16. Ito F., et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64 (2004) 8411-8419
17. Li B., et al. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 125 (2007) 76-87
18. + T cells confers resistance to suppression by virus-induced regulatory T cells. J. Immunol. 180 (2008) 5267-5274
19. Wilcox R.A., et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J. Immunol. 168 (2002) 4262-4267
20. + regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell. Immunol. 226 (2003) 20-29
21. Calarota, S.A. et al. Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule. Vaccine DOI:10.1016/j.vaccine.2008.02.017 (www.sciencedirect.com)
22. Zhou Z., et al. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 5465-5470
23. Bazzoni F., and Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334 (1996) 1717-1725
24. Pollok K.E., et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J. Immunol. 150 (1993) 771-781
25. Ma B.Y., et al. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. Blood 106 (2005) 2002-2010
26. Jang I.K., et al. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-κB. Biochem. Biophys. Res. Commun. 242 (1998) 613-620
27. + T lymphocytes. J. Immunol. 174 (2005) 1898-1905
28. Pineda G., et al. Ubiquitination and TRAF signaling. Adv. Exp. Med. Biol. 597 (2007) 80-92
29. Xia Z.P., and Chen Z.J. TRAF2: a double-edged sword?. Sci. STKE 2005 (2005) e7
30. Cannons J.L., et al. Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. J. Immunol. 163 (1999) 2990-2998
31. Yi K.H., et al. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Res. 67 (2007) 10027-10037
32. + memory T cells and their capacity for secondary expansion. J. Immunol. 175 (2005) 1665-1676
33. Melero I., et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190 (1998) 167-172
34. + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 169 (2002) 4230-4236
35. Ye Z., et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat. Med. 8 (2002) 343-348
36. Arina A., et al. Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. Gene Ther. 15 (2008) 473-483
37. + interferon-producing killer dendritic cells are activated natural killer cells. J. Exp. Med. 204 (2007) 2569-2578
38. Caminschi I., et al. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J. Exp. Med. 204 (2007) 2579-2590
39. + cells identify them as a subset of NK cells. J. Exp. Med. 204 (2007) 2561-2568
40. Kim D.H., et al. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J. Immunol. 180 (2008) 2062-2068
41. Vinay D.S., et al. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J. Immunol. 173 (2004) 4218-4229
42. Teng M.W., et al. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 67 (2007) 7495-7504
43. + T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J. Immunol. 179 (2007) 7295-7304
44. + T cells. J. Leukoc. Biol. 75 (2004) 785-791
45. Chen L., et al. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol. Ther. 15 (2007) 2194-2202
46. Choi B.K., et al. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res. 67 (2007) 8891-8899
47. Piconese S., et al. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205 (2008) 825-839
48. Dubrot J., et al. Absence of surface expression of CD137 (4-1BB) on myeloid-derived suppressor cells. Inmunologia 26 (2007) 121-126
49. Seaman S., et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11 (2007) 539-554
50. Mittler R.S., et al. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J. Exp. Med. 190 (1999) 1535-1540
51. Zhang B., et al. Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J. Clin. Invest. 117 (2007) 3029-3041
52. Arribillaga L., et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 23 (2005) 3493-3499
53. Niu L., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J. Immunol. 178 (2007) 4194-4213
54. Muller A.J., et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 (2005) 312-319
55. + T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110 (2007) 201-210
56. Zhu Y., et al. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109 (2007) 4882-4889
57. Olofsson P.S., et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117 (2008) 1292-1301
58. Jung H.W., et al. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp. Mol. Med. 36 (2004) 13-22
59. Kang Y.J., et al. Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat. Immunol. 8 (2007) 601-609